Table 1B.

The risks of heart failure in ustekinumab‐treated and anti‐tumour necrosis factor‐α inhibitor‐treated groups before inverse probability of treatment weighting

	Number	Event	Person‐years	IR a	HR (95% CI)
					Model 1	Model 2	Model 3	Model 4	Model 5
HF outcome
Anti‐TNF‐α inhibitor	2020	44	3995.02	11.014	1 [reference]	1 [reference]	1 [reference]	1 [reference]	1 [reference]
Ustekinumab	2448	40	5507.33	7.263	0.674 (0.439–1.035)	0.614 (0.4–0.944)	0.612 (0.397–0.942)	0.612 (0.397–0.941)	0.627 (0.407–0.967)

CI, confidence interval; HF, heart failure; HR, hazard ratio; IR, incidence rate; TNF‐α, tumour necrosis factor‐α.

Model 1: nonadjusted. Model 2: adjusted for sex and age. Model 3: adjusted sex, age, diabetes mellitus, hypertension, and dyslipidaemia. Model 4: adjusted sex, age, diabetes mellitus, hypertension, dyslipidaemia, and malignancy. Model 5: adjusted sex, age, diabetes mellitus, hypertension, dyslipidaemia, malignancy, and patients with psoriatic arthritis and severe psoriasis covered by the individual co‐payment beneficiaries programme for rare and intractable disorders.

^a Per 1000 person‐years.